Immutep Limited Stock Investor Sentiment

PRRUF Stock  USD 0.20  0.00  0.00%   
Roughly 62% of Immutep's investor base is looking to short. The analysis of overall sentiment of trading Immutep Limited pink sheet suggests that many investors are alarmed at this time. The current market sentiment, together with Immutep's historical and current headlines, can help investors time the market. In addition, many technical investors use Immutep Limited stock news signals to limit their universe of possible portfolio assets.
Immutep pink sheet news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Immutep daily returns and investor perception about the current price of Immutep Limited as well as its diversification or hedging effects on your existing portfolios.
  
over a year ago at news.google.com         
Immutep A Worthy 2 Dart Throw - Seeking Alpha
Google News at Macroaxis
over two weeks ago at simplywall.st         
Were Hopeful That Zura Bio Will Use Its Cash Wisely
Simply Wall St News at Macroaxis
over three weeks ago at gurufocus.com         
ADAR1 Capital Management, LLC Acquires New Stake in Zura Bio Ltd
Gurufocus Stories at Macroaxis
over a month ago at news.google.com         
Piper Sandler sets price target on Zura Bio shares, cites positive trial data - Investing.com
Google News at Macroaxis
over a month ago at thelincolnianonline.com         
Zura Bio Stock Rating Reaffirmed by Cantor Fitzgerald
news
over a month ago at businesswire.com         
Enveric Biosciences Announces Broad Range of Patent Issuances
businesswire News
over two weeks ago at benzinga.com         
Enveric Biosciences Advances Non-Hallucinogenic DMT Analog Drug With Promising Preclinical Results
benzinga news
over six months ago at globenewswire.com         
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponso...
Macroaxis News: globenewswire.com
over six months ago at investorplace.com         
EFTR Stock Earnings eFFECTOR Therapeutics Meets EPS for Q1 2024
sbwire news
over six months ago at news.google.com         
Head to Head Survey eFFECTOR Therapeutics versus COMPASS Pathways - Defense World
Google News at Macroaxis
over three months ago at benzinga.com         
Dow Jumps 300 Points Alimera Sciences Shares Spike Higher
benzinga news
over two weeks ago at globenewswire.com         
Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology Annua...
Macroaxis News: globenewswire.com
over three weeks ago at simplywall.st         
Is Immix Biopharma In A Good Position To Deliver On Growth Plans?
Simply Wall St News at Macroaxis
over two months ago at news.google.com         
H.C. Wainwright confident in Immix stock growth with progress in NEXICART-2 CAR-T trial - Investing....
Google News at Macroaxis
a day ago at gurufocus.com         
Immix Biopharma Announces 75 percent Complete Response Rate 31. ...
Gurufocus Stories at Macroaxis
over three weeks ago at gurufocus.com         
Biotechnology Value Fund L Ps Strategic Acquisition in Elevation Oncology Inc
Gurufocus Stories at Macroaxis
over a month ago at seekingalpha.com         
Elevation Oncology GAAP EPS of -0.22 misses by 0.02
seekingalpha News
over a month ago at zacks.com         
SAGEs Q3 Loss Wider Than Expected, Revenues Rise YY, Stock Down
zacks News
over two months ago at finance.yahoo.com         
What Makes Elevation Oncology a New Strong Buy Stock
Yahoo News
a day ago at news.google.com         
Long Term Trading Analysis for - Stock Traders Daily
Google News at Macroaxis
over a month ago at finance.yahoo.com         
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones ...
Yahoo News
over three weeks ago at thelincolnianonline.com         
Analysts Offer Predictions for ALX Oncology FY2028 Earnings
news
over two weeks ago at zacks.com         
ALX Oncology Holdings Loses -27.11 percent in 4 Weeks, Heres Why a Trend Reversal May be Around the ...
zacks News
over two months ago at news.google.com         
Point72 Asset Management L.P. Acquires New Holdings in ALX Oncology Holdings Inc. - MarketBeat
Google News at Macroaxis
over a month ago at finance.yahoo.com         
Aadi Bioscience Announces Financial Results for the Third Quarter 2024 and Provides Corporate Update
Yahoo News
over a month ago at thelincolnianonline.com         
Aadi Bioscience Scheduled to Post Earnings on Wednesday
news
over two months ago at investing.com         
Disposition of 9689 shares by David Lennon of Aadi Bioscience at 1.94 subject to Rule 16b-3
Investing News at Macroaxis
over a week ago at news.google.com         
Aadi Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September...
Google News at Macroaxis
few days ago at www.macroaxis.com         
Disposition of 238343 shares by Mallik Ameet of ADC Therapeutics at 3.13 subject to Rule 16b-3
Macroaxis News
over three weeks ago at investing.com         
ADC Therapeutics shareholders approve capital increase
Investing News at Macroaxis
over a month ago at zacks.com         
ADC Therapeutics SA Reports Q3 Loss, Lags Revenue Estimates
zacks News
over a month ago at thelincolnianonline.com         
ADC Therapeutics Set to Announce Quarterly Earnings on Thursday
news
over a month ago at news.google.com         
Discovering Opportunities AlloVir And 2 Other US Penny Stocks - Yahoo Finance
Google News at Macroaxis
over a month ago at gurufocus.com         
Allovir Stock Experiences Significant Decline Amid Negative Financial Performance
Gurufocus Stories at Macroaxis
six days ago at scmp.com         
Syrian rebels at gates of Hama city as civil war reignites
news
over a month ago at accesswire.com         
Did Sana Biotechnology, Inc. Mislead Investors Shareholder Rights Advocates at Levi Korsinsky Invest...
news
over a week ago at gurufocus.com         
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635
Gurufocus Stories at Macroaxis
over three weeks ago at thelincolnianonline.com         
Disposition of 25000 shares by Kovacs Shane William Charles of Olema Pharmaceuticals at 7.02 subject...
news
over two months ago at news.google.com         
Affinity Asset Advisors LLC Invests 2.98 Million in Olema Pharmaceuticals, Inc. - MarketBeat
Google News at Macroaxis
over three weeks ago at gurufocus.com         
Blue Owl Capital Holdings LP Increases Stake in Larimar Therapeutics Inc
Gurufocus Stories at Macroaxis
over a month ago at investing.com         
Cullinan Therapeutics chief scientific officer sells 125,120 in stock
Investing News at Macroaxis
over a month ago at thelincolnianonline.com         
Disposition of 2 shares by Jennifer Michaelson of Cullinan Oncology at 8.76 subject to Rule 16b-3
news
over two months ago at benzinga.com         
Amgens Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Conc...
benzinga news
over six months ago at finance.yahoo.com         
aTyr Pharma to Present Poster Describing Efzofitimods Mechanism of Action at the American Thoracic S...
Yahoo News
over two months ago at gurufocus.com         
FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc
Gurufocus Stories at Macroaxis
over a week ago at news.google.com         
Brokerages Set Zentalis Pharmaceuticals, Inc. Target Price at 10.00 - MarketBeat
Google News at Macroaxis
over a month ago at finance.yahoo.com         
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635
Yahoo News
over a week ago at www.macroaxis.com         
Disposition of 10000 shares by Struthers Richard Scott of Crinetics Pharmaceuticals at 57.57 subject...
Macroaxis News
over three weeks ago at simplywall.st         
Crinetics Pharmaceuticals Third Quarter 2024 Earnings US0.96 loss per share
Simply Wall St News at Macroaxis
over three weeks ago at globenewswire.com         
Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at ...
Macroaxis News: globenewswire.com
over a month ago at zacks.com         
Sage Therapeutics, Inc. Reports Q3 Loss, Tops Revenue Estimates
zacks News
six days ago at businesswire.com         
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635
businesswire News
over two weeks ago at benzinga.com         
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note Here Are Top 5 Initiations For M...
benzinga news
over three weeks ago at simplywall.st         
Viridian Therapeutics Third Quarter 2024 Earnings Revenues Beat Expectations, EPS Lags
Simply Wall St News at Macroaxis
over a month ago at www.macroaxis.com         
Acquisition by Fairmount Funds Management Llc of 1600000 shares of Viridian Therapeutics at 18.75 su...
Macroaxis News
six days ago at thelincolnianonline.com         
10,055 Shares in Cytokinetics, Incorporated Purchased by HighVista Strategies LLC
news
over a week ago at seekingalpha.com         
Cytokinetics application for aficamten accepted by FDA
seekingalpha News
over two weeks ago at investing.com         
Cytokinetics director Wendall Wierenga sells 37,100 in stock
Investing News at Macroaxis
over two weeks ago at zacks.com         
Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan
zacks News
over three weeks ago at finance.yahoo.com         
Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating O...
Yahoo News
over three weeks ago at gurufocus.com         
Logos Global Management LP Reduces Stake in Adverum Biotechnologies Inc
Gurufocus Stories at Macroaxis
over two months ago at thelincolnianonline.com         
Structure Therapeutics Inc. Receives 88.43 Consensus PT from Brokerages
news
over a year ago at news.google.com         
Icosavax Corporate Overview - Marketscreener.com
Google News at Macroaxis
over two weeks ago at gurufocus.com         
Cidara Therapeutics to Participate in Evercore 7th Annual HealthCONx Conference
Gurufocus Stories at Macroaxis
over two months ago at finance.yahoo.com         
Shattuck Labs stock craters following pipeline and job cuts
Yahoo News
over two months ago at news.google.com         
Silence Therapeutics Sees Large Volume Increase - MarketBeat
Google News at Macroaxis
over two weeks ago at zacks.com         
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels
zacks News
over three weeks ago at simplywall.st         
Silence Therapeutics Insider Ups Holding During Year
Simply Wall St News at Macroaxis
over a week ago at zacks.com         
Company News for Dec 2, 2024
zacks News
over a week ago at gurufocus.com         
Applied Therapeutics Receives Complete Response Letter from U.S. ...
Gurufocus Stories at Macroaxis
over a month ago at seekingalpha.com         
Applied Therapeutics GAAP EPS of -0.48, revenue of 0.12M
seekingalpha News
over two months ago at news.google.com         
Applied Therapeutics put volume heavy and directionally bearish - TipRanks
Google News at Macroaxis
over a week ago at gurufocus.com         
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
Gurufocus Stories at Macroaxis
over two weeks ago at zacks.com         
CHMP Endorses AstraZenecas Tagrisso for Expanded Use in NSCLC
zacks News
over three weeks ago at investing.com         
CytomX Therapeutics SWOT analysis biotech stocks potential in cancer treatment
Investing News at Macroaxis
over a month ago at finance.yahoo.com         
CytomX Therapeutics Q3 Earnings and Revenues Top Estimates
Yahoo News
over a year ago at prnewswire.com         
PhenomeX to Participate in Antibody Engineering Therapeutics Europe 2023
prnewswire News
Far too much social signal, news, headlines, and media speculation about Immutep that are available to investors today. That information is available publicly through Immutep media outlets and privately through word of mouth or via Immutep internal channels. However, regardless of the origin, that massive amount of Immutep data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Immutep news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Immutep relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Immutep's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Immutep alpha.

Immutep Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for Immutep Pink Sheet analysis

When running Immutep's price analysis, check to measure Immutep's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immutep is operating at the current time. Most of Immutep's value examination focuses on studying past and present price action to predict the probability of Immutep's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immutep's price. Additionally, you may evaluate how the addition of Immutep to your portfolios can decrease your overall portfolio volatility.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.